Literature DB >> 20536295

Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults.

Karen J Vigil1, Roy F Chemaly.   

Abstract

IMPORTANCE OF THE FIELD: Herpes viruses are associated with a wide spectrum of clinical diseases and impose considerable morbidity and even mortality in immunosuppressed hosts. Although there is no cure for these conditions, available treatments alleviate symptoms, suppress recurrences and reduce the risk of transmission. Valacyclovir was discovered in 1988 and revolutionized the treatment of these infections by virtue of its less frequent dosing regimen, which promotes patient adherence. AREAS COVERED IN THIS REVIEW: This review focuses on the basic principles, mechanisms of action, safety and approved and off-label usage of valacyclovir in the immunocompetent and immunocompromised host. WHAT THE READER WILL GAIN: The reader will have available the current and most up-to-date information on the pharmacology of valacyclovir as well as its clinical use. TAKE HOME MESSAGE: Valacyclovir is a great alternative for the treatment of herpes infections. Now that its patent has expired, new cheaper formulations may start to appear.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536295     DOI: 10.1517/14656566.2010.494179

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.

Authors:  Seul-Ki Kim; Min Chae Kim; Seung Beom Han; Seong Koo Kim; Jae Wook Lee; Nack-Gyun Chung; Bin Cho; Dae Chul Jeong; Jin Han Kang; Hack-Ki Kim
Journal:  Blood Res       Date:  2016-12-23

2.  Valacyclovir in the treatment of acute retinal necrosis.

Authors:  Simon Rj Taylor; Robin Hamilton; Claire Y Hooper; Lavnish Joshi; Jiten Morarji; Nitin Gupta; Sue L Lightman
Journal:  BMC Ophthalmol       Date:  2012-09-05       Impact factor: 2.209

Review 3.  Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature.

Authors:  Lei Wang; Erik A M Verschuuren; Coretta C van Leer-Buter; Stephan J L Bakker; Anoek A E de Joode; Johanna Westra; Nicolaas A Bos
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.